| | | | |
CUSIP No. 758338107 | | Schedule 13D/A | | Page 3 of 7 Pages |
This Schedule 13D/A amends and restates in its entirety the statement on Schedule 13D filed by the Reporting Person with the SEC on July 21, 2017, as previously amended by Amendment No. 1 thereto filed by the Reporting Person with the SEC on August 23, 2017, by Amendment No.2 thereto filed by the Reporting Person with the SEC on November 17, 2017, by Amendment No.3 thereto filed by the Reporting Person with the SEC on January 2, 2018, Amendment No. 4 thereto filed by the Reporting Person with the SEC on April 24, 2018, by Amendment No. 5 thereto filed by the Reporting Person with the SEC on August 23, 2018, by Amendment No. 6 thereto filed by the Reporting Person with the SEC on February 27, 2019 and by Amendment No. 7 thereto filed by the Reporting Person with the SEC on June 4, 2019.
Item 1. | Security and Issuer |
This statement on Schedule 13D/A relates to shares (the “Shares”) of the common stock, par value $0.0001 per share (the“Common Stock”)of Reed’s Inc., a Delaware corporation (the “Issuer”). The principal executive offices of the Issuer are located at 201 Merritt 7 Corporate Park, Norwalk, Connecticut 06851.
Item 2. | Identity and Background |
(a) This statement on Schedule 13D/A is being filed by Raptor/Harbor Reeds SPV LLC, a Delaware limited liability company (the “Reporting Person”). The Reporting Person is filing this Schedule 13D/A to report a reduction in the percentage of Common Stock beneficially owned by the Reporting Person as a result of the Issuer’s underwritten public offering as reported in the Issuer’s Current Report on Form8-K filed with the SEC on April 16, 2020.
(b) The address of the principal office of the Reporting Person is 280 Congress Street, 12th Floor, Boston, Massachusetts 02210.
(c) The name, residence or business address, present principal occupation or employment and citizenship (or state of organization) of each director, executive officer, trustees, general partner, managing member, control person of the Reporting Persons are listed on Schedule I hereto. The principal business of the Reporting Person is to hold shares of Common Stock and other securities of the Issuer.
(d) During the last five years, neither the Reporting Person nor any of the persons named in Schedule I has been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors).
(e) During the last five years, neither the Reporting Person nor any of the persons named in Schedule I was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding has been or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, U.S. federal or state securities laws or finding any violations with respect to such laws.
Item 3. | Source and Amount of Funds or Other Consideration |
The Reporting Person purchased the issued Shares, and will purchase the shares of Common Stock issuable upon exercise of the Warrants and conversion of the Note, in the ordinary course of its business as a private investment fund utilizing the Reporting Person’s working capital. The purchase price paid for the issued Shares was $3,703,970, the purchase price paid for the Note was $3,400,000 and the aggregate purchase price to be paid upon exercise of the Warrants will be $5,592,999, representing an aggregate purchase price of $12,696,969.
Item 4. | Purpose of Transaction |
The Reporting Person acquired the issued Shares, and will acquire the Shares issuable upon exercise of the Warrants and conversion of the Note, for investment purposes, and such purchases have been, and will be, made in the Reporting Person’s ordinary course of business.
The Reporting Person expects to review from time to time its investment in the Issuer and may, depending on the market and other conditions: (i) exercise the Warrants and covert the Note, (ii) purchase additional shares of Common Stock, warrants, convertible debt, options or related derivatives in the open market, in privately negotiated transactions or otherwise and (iii) sell all or a portion of the Shares now beneficially owned or any shares of